Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Sarcoma 1Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Liposarcoma 1Leukoplakia, Oral 1Head and Neck Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Hepatocellular 1Adenocarcinoma, Follicular 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 37Radiotherapy 31Oxaliplatin 29Cisplatin 28Paclitaxel 24Leucovorin 22Irinotecan 19Docetaxel 13pembrolizumab 10Capecitabine 10Carboplatin 9Radiation 8Neoadjuvant Therapy 8Cetuximab 8Surgical Procedures, Operative 7Folfox protocol 7Chemotherapy, Adjuvant 6Nivolumab 5Gefitinib 5Taxes 4Erlotinib Hydrochloride 4Biopsy 4durvalumab 3Panitumumab 3Itraconazole 3Epirubicin 3Bevacizumab 3tremelimumab 2spartalizumab 2ixabepilone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenocarcinoma Of Esophagus × Rosiglitazone × Clear all
NCT04114136 2026-04-24

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

University of Pittsburgh

Phase 2 Recruiting
72 enrolled
DermatologicGastrointestinalHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡